O'Donnell Niall
O'Donnell Niall's purchase track record
O'Donnell Niall has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2023 | OKUR | $1.00M | -28.4% | -17.5% | +5.5% |
| 2/16/2023 | SPRB | $2.00M | -10.0% | -7.2% | +6.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Transaction History
| OKUR | ▲ Buy | Open Market | 125,000 | $1.0M | 5/8/2023 | View on chart |
| SPRB | ▲ Buy | Open Market | 630,400 | $2.0M | 2/16/2023 | View on chart |
| MIRM | ▼ Sell | Open Market | 93,770 | $1.8M | 11/15/2022 | View on chart |
| MIRM | ▼ Sell | Open Market | 32,109 | $629K | 11/14/2022 | View on chart |
| MIRM | ▼ Sell | Open Market | 174,121 | $3.5M | 11/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.